×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
MPN
Brielle Urciuoli
Diagnosing and treating the disease before it turns into AML is a key area of study, said Srdan Verstovsek, M.D., Ph.D., medical oncologist and professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.
Katie Kosko
Researchers discovered that at least 50 percent of people surveyed had an employment change because of their disease.
Laura Michaelis, M.D.
Genomics are starting to play a crucial role in treatment planning for patients with essential thrombocythemia.
BRADY L . STEIN, M.D., M.H.S.
Patients with essential thrombocythemia should know the signs and symptoms of blood clots.
Kathleen Weis, CEO
Since these are difficult diseases to treat, research has been quite slow over the last decade or so, but continues to pick up, developing new treatments for patients with these diseases.
Katie Kosko
“What we really want this to do is be a place for patients to facilitate conversations with their doctor,” Michelle Woehrle, executive director of MPN Research Foundation (MPNRF) said.
Kristie L. Kahl
Recent research showed first-degree relatives of patients with certain types of blood cancers may be at an increased risk for such disease, highlighting the importance of counseling, gene testing and surveillance.
Brielle Urciuoli
"The objective is to equip the research and drug development communities with the data needed to move better MPN treatments, and potentially, cures, through the discovery pipeline more quickly."
Kristie L. Kahl
A national survey demonstrated shared feelings across all blood cancer types about treatment options and their side effects, as well as other social, financial and emotional aspects.
The award recognizes individuals and organizations who are making a difference in the myeloproliferative neoplasm community